Actively Recruiting
Unbound Cloxacillin Concentrations During Continuous Infusion
Led by Emeli Månsson · Updated on 2026-02-17
25
Participants Needed
1
Research Sites
98 weeks
Total Duration
On this page
Sponsors
E
Emeli Månsson
Lead Sponsor
R
Region Västmanland
Collaborating Sponsor
AI-Summary
What this Trial Is About
Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too high nor too low. A PK/PD model will be developed to predict which dosage of cloxacillin is appropriate for an individual based on age, gender, kidney function, and serum-protein level.
CONDITIONS
Official Title
Unbound Cloxacillin Concentrations During Continuous Infusion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Treating physician has decided to start continuous infusion of cloxacillin
You will not qualify if you...
- Unwilling or unable to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Västmanlands sjukhus Västerås
Västerås, Sweden
Actively Recruiting
Research Team
E
Emeli Månsson, PhD
CONTACT
K
Karl-Johan Lindner, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here